BIORA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.607 USD | -2.08% |
|
+1.25% | -55.04% |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Biora Therapeuti...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Companyâs pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6199
USD
Average target price
10.3
USD
Spread / Average Target
+1,561.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.04% | 22.24M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- BIOR Stock
- News Biora Therapeutics, Inc.
- Transcript : Biora Therapeutics, Inc., Q2 2022 Earnings Call, Aug 15, 2022
